UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Microstructure and hydrogen storage property of Mg/MWNTs composites

Journal of alloys and compounds, 2004-06, Vol.372 (1), p.231-237

2004

Volltextzugriff (PDF)

Alloying effects of transition metals on chemical bonding in magnesium hydride MgH2

Acta materialia, 2004-01, Vol.52 (2), p.521-528

2004

Volltextzugriff (PDF)

166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study

Annals of oncology, 2022-05, Vol.33, p.S199-S199

2022

Volltextzugriff (PDF)

73TiP Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3

Annals of oncology, 2023-11, Vol.34, p.S1493

2023

Volltextzugriff (PDF)

379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study

Annals of oncology, 2023-10, Vol.34, p.S337-S337

2023

Volltextzugriff (PDF)

108P Copy loss enrichment at metastatic disease progression in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibition

Annals of oncology, 2022-09, Vol.33, p.S587-S588

2022

Volltextzugriff (PDF)

383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study

Annals of oncology, 2023-10, Vol.34, p.S338-S339

2023

Volltextzugriff (PDF)

51P ctDNA analyses at baseline in patients with ER-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC) treated with imlunestrant in the EMBER phase I study

ESMO open, 2024-05, Vol.9, p.103058, Article 103058

2024

Volltextzugriff (PDF)

212P A phase Ib/II study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer

ESMO open, 2024-05, Vol.9, p.103234, Article 103234

2024

Volltextzugriff (PDF)

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer: Turner NC, Ro J, André F, et al (Royal Marsden Hosp, London, UK; National Cancer Ctr, Goyang-si, South Korea; Inst Gustave Roussy, Villejuif, France; et al) N Engl J Med 373:209-219, 2015

Breast diseases, 2016, Vol.27 (4), p.314-315

2016

Volltextzugriff (PDF)

Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors

The Year book of oncology, 2010-01, Vol.2010, p.11-13

2010

Volltextzugriff (PDF)

257TiP VERITAC-2: A global, randomized phase III study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

ESMO open, 2023-05, Vol.8 (1), p.101445, Article 101445

2023

Volltextzugriff (PDF)

205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

ESMO open, 2023-05, Vol.8 (1), p.101394, Article 101394

2023

Volltextzugriff (PDF)

Risk factors for infant maltreatment: a population-based study

Child abuse & neglect, 2004-12, Vol.28 (12), p.1253-1264

2004

Volltextzugriff (PDF)

general framework for analyzing the genetic architecture of developmental characteristics

Genetics (Austin), 2004-03, Vol.166 (3), p.1541-1551

2004

Volltextzugriff (PDF)

RESEARCH ON EMERGENCY LOGISTICS DYNAMIC NETWORK BASED ON SUPER-NETWORK

Latin American applied research, 2017-01, Vol.47 (1), p.11-16

2017

Volltextzugriff (PDF)

Starch Properties of Mutant Rice High in Resistant Starch

Journal of agricultural and food chemistry, 2006-01, Vol.54 (2), p.523-528

2006

Volltextzugriff (PDF)

Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors : Wang L, Ellsworth KA, Moon I, et al (Mayo Clinic, Rochester, MN; et al) Cancer Res 70:319-328, 2010

Breast diseases, 2010, Vol.21 (3), p.266-267

2010

Volltextzugriff (PDF)

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Breast diseases, 2016, Vol.27 (4), p.314-315

2016

Volltextzugriff (PDF)

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT: Chia S, Gradishar W, Mauriac L, et al (Univ of British Columbia, Vancouver, Canada) J Clin Oncol 26:1664-1670, 2008

Breast diseases, 2009, Vol.20 (1), p.94-95

2009

Volltextzugriff (PDF)

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

Breast diseases, 2009-01, Vol.20 (1), p.94-95

2009

Volltextzugriff (PDF)

Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer

Breast diseases, 2009-01, Vol.20 (3), p.327-328

2009

Volltextzugriff (PDF)

Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group: Paridaens RJ, Dirix LY, Beex LV, et al (Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; Algemeen Ziekenhuis Sint Augustinus, Antwerp; Université Libre de Bruxelles; et al) J Clin Oncol 26:4883-4890, 2008

Breast diseases, 2009, Vol.20 (3), p.331-332

2009

Volltextzugriff (PDF)

Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

Breast diseases, 2009-01, Vol.20 (3), p.331-332

2009

Volltextzugriff (PDF)

Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer: McCowan C, Shearer J, Donnan PT, et al (Univ of Dundee, UK; Ninewells Hosp and Med School, Dundee, UK; et al) Br J Cancer 99:1763-1768, 2008

Breast diseases, 2009, Vol.20 (3), p.327-328

2009

Volltextzugriff (PDF)

1 – 25 von 252

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(233)
Mit Volltextzugriff
(215)

Publikationsform

Sprache

Englisch
(247)
Französisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(119)
Life Sciences & Biomedicine
(54)
Physics
(53)
Technology
(50)
Physical Sciences
(47)
Exact Sciences And Technology
(39)
Materials Science
(28)
Engineering
(21)
Materials Science, Multidisciplinary
(19)
Engineering, Mechanical
(15)
Thermodynamics
(15)
Mechanics
(13)
Physics, Nuclear
(13)
Physics, Particles & Fields
(13)
Agriculture
(12)
Astronomy & Astrophysics
(12)
Besiii
(12)
Animals
(11)
Applied Sciences
(11)
Biological And Medical Sciences
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Microstructure and hydrogen storage property of Mg/MWNTs composites

Alloying effects of transition metals on chemical bonding in magnesium hydride MgH2

166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study

73TiP Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3

379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study

108P Copy loss enrichment at metastatic disease progression in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibition

383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study

51P ctDNA analyses at baseline in patients with ER-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC) treated with imlunestrant in the EMBER phase I study

212P A phase Ib/II study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer: Turner NC, Ro J, André F, et al (Royal Marsden Hosp, London, UK; National Cancer Ctr, Goyang-si, South Korea; Inst Gustave Roussy, Villejuif, France; et al) N Engl J Med 373:209-219, 2015

Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors

257TiP VERITAC-2: A global, randomized phase III study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

Risk factors for infant maltreatment: a population-based study

general framework for analyzing the genetic architecture of developmental characteristics

RESEARCH ON EMERGENCY LOGISTICS DYNAMIC NETWORK BASED ON SUPER-NETWORK

Starch Properties of Mutant Rice High in Resistant Starch

Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors : Wang L, Ellsworth KA, Moon I, et al (Mayo Clinic, Rochester, MN; et al) Cancer Res 70:319-328, 2010

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer

Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer: McCowan C, Shearer J, Donnan PT, et al (Univ of Dundee, UK; Ninewells Hosp and Med School, Dundee, UK; et al) Br J Cancer 99:1763-1768, 2008

Suchergebnisse filtern